Our work provides rationale for combining JNK inhibition and chemotherapy against metastatic breast cancer, and these results may be of particular importance when considering basal‐like breast cancer, against which few targeted therapeutic options are available beyond classical chemotherapy regimens. Here, MAPK8 is linked to breast carcinoma.